Gene therapeutic exploration: Retrovirus-mediated soluble vascular endothelial growth factor receptor-2 (sFLK-1) inhibits the tumorigenicity of S180, MCF-7, and B16 cells in vivo

Oncology Research

Volumn 15, Issue 5, 2005, Pages 239-247

  Kou, Baijun ^a,b   Li, Yulin ^a   Shi, Yingai ^a   Xia, Jianxin ^a   Wang, Xinrui ^a   Wu, Shan ^a  

^a JILIN UNIVERSITY   (China)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Angiogenesis; Gene therapy; Retroviral vector; Soluble receptor; Tumor growth; VEGF

Indexed keywords

CYCLINE; PROTEIN TYROSINE KINASE; RECOMBINANT VASCULOTROPIN; RETROVIRUS VECTOR; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; BREAST ADENOCARCINOMA; CANCER INHIBITION; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; EMBRYO; FIBROBLAST; GENE THERAPY; HUMAN; HUMAN CELL; IN VIVO STUDY; MELANOMA CELL; METASTASIS; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA CELL; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM; VIRUS TITRATION; WESTERN BLOTTING;

EID: 26244453690     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504005776404616     Document Type: Article

References (33)

1. Folkman, J. Anti-angiogenesis: New concept for therapy of solid tumors. Ann. Surg. 175:409-416; 1972.
2. Folkman, J.; Ingber, D. Inhibition of angiogenesis. Semin. Cancer Biol. 3:89-96; 1992.
3. Davidoff, A. M.; Leary, M. A.; Ng, C. Y. C.; Vanin, E. F. Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo. J. Pediatr. Surg. 36B:30-36; 2001.
4. Bicknell, R.; Harris, A. L. Mechanisms and therapeutic implications of angiogenesis. Curr. Opin. Oncol. 8:60-65; 1996.
5. Pluda, J. M. Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies. Semin. Oncol. 24:203-218; 1997.
6. Folkman, J. Antiangiogenic gene therapy. Proc. Natl. Acad. Sci. USA 95:9064-9066; 1998.
7. Lau, K.; Bicknell, R. Antiangiogenic gene therapy. Gene Ther. 6:1793-1795; 1999.
8. Kleinman, H. K.; Liau, G. Gene therapy for antiangiogenesis. J. Natl. Cancer Inst. 93:965-967; 2001.
9. Millauer, B.; Longhi, M. P.; Plate, K. H.; Shawver, L. K.; Risau, W.; Ullrich, A.; Strawn, L. M. Dominant-negative inhibition of flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56:1615-1620; 1996.
10. Folkman, J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 285:1182-1186; 1971.
11. Gimbrone, M. A.; Leapman, S. B.; Cotran, R. S.; Folkman, J. Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 136:261-276; 1972.
12. Tanaka, T.; Manome, Y.; Wen, P.; Kufe, D. W.; Fine, H. A. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat. Med. 3:437-442; 1997.
13. Kong, H. L.; Hecht, D.; Song, W.; Kovesdi, I.; Hackett, N. R.; Yayon, A.; Crystal, R. G. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum. Gene Ther. 9(6):823-833; 1998.
14. Davidoff, A. M.; Leary, M. A.; Ng, C. Y.; Vanin, E. F. Retroviral vector-producer cell mediated angiogenesis inhibition restricts neuroblastoma growth in vivo. Med. Pediatr. Oncol. 35:638-640; 2000.
15. Kuo, C. J.; Farnebo, F.; Yu, E. Y.; Christofferson, R.; Swearingen, R. A.; Carter, R.; von Recum, H. A.; Yuan, J.; Kamihara, J.; Flynn, E.; D'Amato, R.; Folkman, J.; Mulligan, R. C. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc. Natl. Acad. Sci. USA 98(8):4605-4610; 2001.
16. Geng, L.; Donnelly, E.; Mcmahon, G.; Lin, P. C.; Sierra-Rivera, E.; Oshinka, H.; Hallahan, D. E. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 61:2413-2419; 2001.
17. Kou, B.; Li, Y.; Zhang, L.; Zhu, G.; Wang, X.; Li, Y.; Xia, J.; Shi, Y. In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment. Exp. Mol. Pathol. 76(2): 129-137; 2004.
18. Senger, D. R.; Galli, S. J.; Dvorak, A. M.; Perruzzi, C. A.; Harvey, V. S.; Dvorak, F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985; 1983.
19. Keck, P. J.; Hauser, S. D.; Krivl, G.; Sanzo, K.; Warren, T.; Feder, J.; Connolly, D. T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246:1309-1312; 1989.
20. Abedi, H.; Zachary, I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J. Biol. Chem. 272:15442-15451; 1997.
21. Waltenberger, J.; Claesson-Welsh, L.; Siegbahn, A.; Shibuya, M.; Heldin, C. H. Different signal transduction properties of KDR and Flt-1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269:26988-26995; 1994.
22. Risau, W. Mechanism of angiogenesis. Nature 386:671-674; 1997.
23. Carmeliet, P.; Ferreira, V.; Breier, G.; Pollefeyt, S.; Kieckens, L.; Gertsenstein, M.; Fahrig, M.; Vandenhoeck, Á.; Harpal, K.; Eberhardt, C.; Declercq, C.; Pawling, J.; Moons, L.; Collen, D.; Risau, W.; Nagy, A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435-444; 1996.
24. Shalaby, F.; Rossant, J.; Yamaguchi, T. P.; Gertsenstein, M.; Wu, X. F.; Breitman, M. L.; Schuh, A. C. Failure of blood island formation and vasculogenesis in flk-1 deficient mice. Nature 376:62-66; 1995.
25. Davis, S. T.; Chen, H.; Park, J.; Presta, L. G.; Ferrara, N. The second immunoglobulin like domain of the VEGF tyrosine kinase receptor FLK-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J. 15:4919-4927; 1996.
26. Davidoff, A. M.; Leary, M. A.; Ng, C. Y.; Vanin, E. F. Retroviral vector-producer cell mediated angiogenesis inhibition restricts neuroblastoma growth in vivo. Med. Pediatr. Oncol. 35(6):638-640; 2000.
27. Davidoff, A. M.; Leary, M. A.; Ng, C. Y.; Vanin, E. F. Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo. J. Pediatr. Surg. 36(1):30-61; 2001.
28. Davidoff, A. M.; Ng, C. Y.; Brown, P.; Leary, M. A.; Spurbeck, W. W.; Zhou, J.; Horwitz, E.; Vanin, E. F.; Nienhuis, A. W. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin. Cancer Res. 7(9):2870-2879; 2001.
29. Tseng, J. F.; Farnebo, F. A.; Kisker, O.; Becker, C. M.; Kuo, C. J.; Folkman, J.; Mulligan, R. C. Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk 1 delays the growth of murine and human pancreatic adenocarcinoma in mice. Surgery 132(5):857-865; 2002.
30. Savontaus, M. J.; Sauter, B. V.; Huang, T. G.; Woo, S. L. Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells. Gene Ther. 9(14): 972-979; 2002.
31. Becker, C. M.; Farnebo, F. A.; Iordanescu, I.; Behonick, D. J.; Shih, M. C.; Dunning, P.; Christofferson, R.; Mulligan, R. C.; Taylor, G. A.; Kuo, C. J.; Zetter, B. R. Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor flk1. Cancer Biol. Ther. 1(5):548-553; 2002.
32. Tamiya, T.; Wei, M. X.; Chase, M.; Ono, Y.; Lee, F.; Breakefield, X. O.; Chiocca, E. A. Transgene inheritance and retroviral infection contribute to the efficiency of gene expression in solid tumors inoculated with retroviral vector producer cells. Gene Ther. 2(8):531-538; 1995.
33. Davidoff, A. M.; Nathwani, A. C.; Spurbeck, W. W.; Ng, C. Y.; Zhou, J.; Vanin, E. F. rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice. Cancer Res. 62(11):3077-3083; 2002.